Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Ascites in liver cirrhosis is explained by increased production of vasoactive substances leading to renal vasoconstriction and salt and water retention. The retained water then accumulates in the peritoneal cavity under the effect of portal hypertension and low albumin. Refractory ascites is defined as ascites that cannot be mobilized or prevented from early recurrence after large-volume paracentesis despite medical therapy and dietary sodium restriction. Midodrine is an α1 receptor agonist that can improve systemic and renal hemodynamics in non-azotemic cirrhotic patients by counteracting mesenteric vasodilatation, which is accentuated in cirrhosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Liver Institute, Egypt
• Treatments: Midodrine

Criteria

Inclusion Criteria:

• Children aged 7-18 years

• Both sexes

• Having refractory ascites (not responding to maximal dose of diuretics

• Diuretic-induced complications necessitate discontinuation of the drug

Exclusion Criteria:

• Non-cirrhotic causes of ascites

• Intrinsic renal disease ( e.g; polycystic kidney disease)

• Active gastrointestinal bleeding or the presence of risky varices

• Patients with Portal vein thrombosis and Budd-Chiari

• Cardiovascular disease

• Systemic hypertension or prehypertension

• Hyperthyroidism

• Patients with narrow-angle glucoma